{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T23:29:45Z","timestamp":1773530985126,"version":"3.50.1"},"reference-count":5,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.ophtha.2020.01.047","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T02:00:45Z","timestamp":1592445645000},"page":"e43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Re: Goldberg et\u00a0al.: A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease (Ophthalmology. 2019;126:1230\u20131237)"],"prefix":"10.1016","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6122-1104","authenticated-orcid":false,"given":"Mumta","family":"Kanda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2020.01.047_bib1","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.ophtha.2019.03.050","article-title":"A\u00a0phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease","volume":"126","author":"Goldberg","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.01.047_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12177-008-9006-2","article-title":"Quantitative assessment of tear production: a review of methods and utility in dry eye drug discovery","volume":"1","author":"Senchyna","year":"2008","journal-title":"J\u00a0Ocul Biol Dis Infor"},{"key":"10.1016\/j.ophtha.2020.01.047_bib3","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/00006324-199302000-00011","article-title":"Schirmer test. I. A review","volume":"70","author":"Cho","year":"1993","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.ophtha.2020.01.047_bib4","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/00003226-200404000-00010","article-title":"The repeatability of clinical measurements of dry eye","volume":"23","author":"Nichols","year":"2004","journal-title":"Cornea"},{"key":"10.1016\/j.ophtha.2020.01.047_bib5","first-page":"CD010051","article-title":"Topical cyclosporine A therapy for dry eye syndrome","volume":"9","author":"de Paiva","year":"2019","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642020300907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642020300907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:08:53Z","timestamp":1758982133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642020300907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":5,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0161642020300907"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2020.01.047","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re: Goldberg et\u00a0al.: A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease (Ophthalmology. 2019;126:1230\u20131237)","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2020.01.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2019.03.050","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}